Regenerative medicine · Kidney failure
Trestle Biotherapeutics
A San Diego company building implantable, stem cell derived kidney tissue on biofabrication science licensed from Harvard. Four years after that license it is still preclinical: no registered trial, no published kidney data of its own, and no Form D on file.
A channel written through a crowd of organoids
In 2019 a team in Jennifer Lewis’s lab at Harvard packed hundreds of thousands of stem cell derived organoids into one dense living matrix, pushed a needle through it and drew a path back out. The matrix closed behind the needle, leaving a tube that could be perfused. They called the method sacrificial writing in functional tissue, or SWIFT.
The tissue they used to prove it was cardiac. The team “created a perfusable cardiac tissue that fuses and beats synchronously over a 7-day period.” Not a kidney. A piece of heart, in a dish, for a week.
Three years later a small San Diego startup licensed that method, and a stack of related kidney biology, to make something a surgeon could put inside a person whose kidneys have stopped. The founders chose a name that says where they stand: “A trestle is a bridge which rests on the support of underlying and interconnected braces.” The braces here are other people’s laboratories.
Two options, and both are old
A person whose kidneys fail has dialysis or a transplant, and both are about seventy years old. The company puts the US dialysis population near 600,000 and the waiting list near 100,000 against roughly 25,000 transplants a year.
The field is candid about the difficulty. A 2024 Kidney International review set out the two routes to a stem cell based renal replacement therapy and concluded: “Neither of these approaches has yet been successful, and both have remaining challenges.” Organoids grow nephrons, but without a plumbed exit. “As a result, nephron number is limited, and there is no integrated connection for the filtrate to exit the kidney.” Transplanted organoids also throw off unwanted cell types, cartilage among them. No regenerative kidney therapy is approved anywhere.
Two Organovo veterans and a chairman from Frazier
Ben Shepherd is a vascular biologist and tissue engineer, a Yale postdoc in Jordan Pober’s lab and a board certified cardiovascular perfusionist. He spent more than a decade in industry, ending as vice president of research and preclinical development at Organovo, the San Diego bioprinting company. Alice Chen, his co-founder and chief scientific officer, was director of research and preclinical development at the same company.
When Harvard announced the license in February 2022, 3DPrint.com put it plainly: “Though this is an exciting announcement, we have heard similar promises by companies over the years.” The piece pointed at Organovo’s stalled liver program and noted that both quoted Trestle executives came from there.
A third founder rarely appears in the company’s own materials. SEC filings by Frazier Lifesciences Acquisition Corp describe Robert F. Baltera as co-founder and executive chairman of Trestle since April 2020, alongside his role as an entrepreneur in residence at Frazier Life Sciences; a Palisade Bio proxy filed in April 2026 still lists him on the board. The advisory bench is strong for a company this size: Jennifer Lewis and Ryuji Morizane, whose labs produced the licensed work, and Laura Niklason, founder and chief executive of Humacyte.
Licenses, a prize, then quiet
The building is mostly in-licensing. Harvard’s Office of Technology Development granted the kidney engineering license on February 8, 2022. A week later Trestle licensed methods from Ryuichi Nishinakamura at Kumamoto University for making ureteric bud and nephron progenitor cells, the two populations a kidney is built from. In May 2023 it joined Wellcome Leap’s HOPE program, a $50 million effort with Lewis leading the kidney team, and a month later won $1 million from KidneyX as one of eight Artificial Kidney Prize Phase 2 winners.
In March 2025 it announced a research collaboration and material transfer agreement with Humacyte, whose acellular vessel won FDA approval in December 2024 for vascular trauma, to test whether that vessel can perfuse Trestle tissue. No terms were given. The company’s news page has posted nothing since.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| Registered trials | A ClinicalTrials.gov query for Trestle Biotherapeutics on September 23, 2026 returned zero studies. No first in human study is registered. | Not found |
| FDA record | No 510(k), no premarket approval, no licensed biologic. A tissue therapy of this kind needs an investigational new drug application before a patient can be dosed, and none has been announced. | Not found |
| Trestle papers | PubMed lists two papers with a Trestle Biotherapeutics affiliation: a 2024 Development paper on trophoblast stem cells, with Alice Chen as an author, and a 2022 Drug Metabolism and Disposition paper from Janssen listing J. W. Higgins at Trestle. Neither reports kidney tissue. | Public record |
| The licensed science | Peer reviewed, and in vitro. Flow enhanced vascularization of human kidney organoids on a chip (Nature Methods, 2019). Bioprinted organoids with better reproducibility (Nature Materials, 2021). SWIFT, whose published exemplar was cardiac, not renal (Science Advances, 2019). | Peer reviewed |
| In vivo data | None published by Trestle. Its 2023 KidneyX proposal lists as Aim 3 that “we will assess the behavior and performance of the bioengineered kidney tissues, in vivo.” No species, implant site, duration or filtration data has been reported since. | Not found |
| Federal prize | $1,000,000, KidneyX Artificial Kidney Prize Phase 2, June 12, 2023, one of eight winners. The funds would “advance their pre-clinical R&D efforts to scale early prototype designs.” | Public record |
| Federal grants | No NIH or NSF award. NIH RePORTER matches for the word Trestle belong to Trestle Optics, an unrelated microscopy company in Irvine. | Not found |
| Patents | PitchBook lists four pending applications on the company profile, all first filed October 3, 2024, on ureteric bud kidney tissues and on vascularization of kidney tissues. The foundational IP is not Trestle’s to own: a June 2025 Lewis lab preprint states that “Trestle Biotherapeutics, Inc. has licensed patents related to kidney tissue engineering from Harvard University” and names Harvard and the General Hospital Corporation as applicants on a related filing. | Public record |
| Partnerships | Wellcome Leap HOPE performer, May 25, 2023, share undisclosed. Humacyte research collaboration and material transfer agreement, March 6, 2025, terms undisclosed, no results reported. | Company-stated |
Read plainly: the licensed science is first rate and published, the team has built tissue before, and a federal prize panel put the plan among eight winners. What does not exist in any public record is a single Trestle result: no animal study, no paper, no filing, no trial. The company is consistent about the stage, calling itself preclinical in every release since 2022. Its forward statements are looser. Tissue that “will get patients off dialysis, delay their need for transplantation, and one day become replacement organs” is an intention, and it has been the same sentence since 2021.
What to watch
- A first in vivo result, with species, implant site, duration and measured function stated. That is the gap between this company and every claim made about it.
- Any Trestle authored paper on kidney tissue. There is none.
- An announced IND, or a registered study.
- Output from the Humacyte work: whether that vessel actually perfuses a kidney construct, and in what model.
- A financing. The last recorded event on PitchBook’s timeline is September 20, 2024, and no Form D has ever been filed. The company’s news page has posted nothing since March 2025.
In their words
“Trestle has embarked on an effort that is really ambitious, but the hundreds of thousands of patients living with kidney failure in the U.S. alone deserve better than the burdensome standard-of-care that was developed nearly 70 years ago.”
Ben Shepherd, co-founder and CEO, KidneyX release, June 2023 · Company release
“Patients living with kidney failure have had the same two standard-of-care treatment options for more than 60 years.”
Ben Shepherd, on the Harvard license, February 2022 · Company release
“Trestle was founded with the belief that recreating patterns and processes found in nature is key to building functional tissues.”
Alice Chen, co-founder and CSO, quoted in VoxelMatters, February 2022 · Independent
“Most recently, we developed a new biomanufacturing method, known as sacrificial writing in functional tissue (SWIFT), that enables the fabrication of vascularized kidney tissues.”
Jennifer A. Lewis, Wyss Institute, Harvard release, February 2022 · Licensor release
“Trestle is doing cutting edge work in a field that desperately needs innovation and risk-taking.”
Laura Niklason, founder and CEO of Humacyte, March 2025 · Partner release
“Though this is an exciting announcement, we have heard similar promises by companies over the years.”
Michael Molitch-Hou, 3DPrint.com, February 2022 · Independent
“Neither of these approaches has yet been successful, and both have remaining challenges.”
van den Berg, Dumas, Little and Rabelink, Kidney International, 2024 · Peer reviewed
Related companies
Sources
- Public recordDatabase queries: ClinicalTrials.gov, PubMed, NIH RePORTER, SEC EDGAR
- Public recordFrazier Lifesciences Acquisition Corp annual report naming Baltera as Trestle co-founder
- Public recordWinning Solution: Bioengineered Therapies for Kidney Failure
- Peer reviewedBiomanufacturing of organ-specific tissues with embedded vascular channels (SWIFT)
- Peer reviewedFlow-enhanced vascularization and maturation of kidney organoids in vitro
- Peer reviewedChallenges in maturation and integration of kidney organoids
- PreprintPerfusable 3D models of ureteric bud and collecting duct tubules
- IndependentHarvard Bioprinting Tech Licensed to Ex-Organovo Execs
- IndependentTrestle Biotherapeutics emerges to bioprint implantable kidney tissues
- IndependentTrestle Biotherapeutics Wins Prestigious KidneyX Prize
- LicensorHarvard licenses kidney engineering technology to Trestle
- CompanyLicense agreement with Kumamoto University
- CompanyTrestle Bio Announces Research Collaboration with Humacyte
- CompanyCompany website, founders’ letter, news and advisers
- DatabaseCompany profile, funding timeline and patent list
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
